Acute Myeloid Leukemia- Composite Model

Introduction

This website was developed to provide an accurate method to calculate a total AML-CM score that can be used to predict mortality after initial therapy for patients with newly diagnosed AML. The AML-CM comprises of the augmented HCT-CI to capture comorbidity burdens, patient’s age and cytogenetic/molecular risks per the European Leukemia Network (ELN) classification [1] to capture AML resistance to therapy.

This information can only be used by experienced physicians in the context of other risk factors for mortality such as the degree of cancer severity and the type of treatment regimen.

The AML-CM was designed and validated in a group of 1100 patients with newly diagnosed AML, who were treated between 2008-2012 at five academic institutions led by the Seattle Cancer Care Alliance (SCCA)/Fred Hutchinson Cancer Research Center (FHCRC), Massachusetts General Hospital, Cleveland Clinic, Stanford University, University of Utah.